Your browser is no longer supported. Please, upgrade your browser.
Trevena, Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own1.80% Shs Outstand161.27M Perf Week-12.14%
Market Cap245.16M Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float159.74M Perf Month-15.56%
Income-29.40M PEG- EPS next Q-0.08 Inst Own14.20% Short Float12.60% Perf Quarter-47.40%
Sales3.10M P/S79.08 EPS this Y15.20% Inst Trans-0.25% Short Ratio5.30 Perf Half Y-35.86%
Book/sh0.82 P/B1.85 EPS next Y32.30% ROA-33.00% Target Price- Perf Year62.31%
Cash/sh0.68 P/C2.24 EPS next 5Y- ROE-39.20% 52W Range0.92 - 3.68 Perf YTD-28.97%
Dividend- P/FCF- EPS past 5Y27.60% ROI-28.60% 52W High-58.70% Beta2.47
Dividend %- Quick Ratio7.20 Sales past 5Y-13.30% Gross Margin94.10% 52W Low65.60% ATR0.14
Employees25 Current Ratio7.20 Sales Q/Q122.60% Oper. Margin- RSI (14)37.02 Volatility8.25% 9.70%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.90% Profit Margin- Rel Volume1.16 Prev Close1.63
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume3.80M Price1.52
Recom2.00 SMA20-12.99% SMA50-19.18% SMA200-32.80% Volume4,424,297 Change-6.75%
Mar-15-21Initiated Oppenheimer Perform
Sep-14-20Initiated Guggenheim Buy $5
Aug-28-20Initiated Cantor Fitzgerald Overweight $5
May-31-19Resumed H.C. Wainwright Buy
Nov-05-18Downgrade H.C. Wainwright Buy → Neutral
Oct-12-18Downgrade Needham Buy → Hold
Oct-10-18Downgrade Jefferies Buy → Hold
Nov-08-17Reiterated Needham Buy $9 → $7
Oct-16-17Downgrade Barclays Overweight → Equal Weight $15 → $2.50
Oct-12-17Reiterated H.C. Wainwright Buy $8 → $7
May-08-17Reiterated Needham Buy $11 → $9
Feb-23-17Reiterated H.C. Wainwright Buy $11 → $8
Feb-22-17Reiterated FBR & Co. Outperform $13 → $8
Feb-02-17Initiated Ladenburg Thalmann Buy $15
Jan-09-17Initiated H.C. Wainwright Buy $11
Jan-05-17Initiated Oppenheimer Outperform
May-17-16Reiterated Needham Buy $14 → $11
May-17-16Reiterated FBR Capital Outperform $13 → $16
Mar-29-16Initiated FBR Capital Outperform $16
Sep-01-15Reiterated Wedbush Outperform $15 → $20
May-06-21 10:29AM  
May-05-21 07:00AM  
Apr-29-21 07:00AM  
Apr-21-21 07:55AM  
Apr-15-21 07:30AM  
Mar-30-21 07:15AM  
Mar-18-21 07:00AM  
Mar-09-21 07:00AM  
Mar-05-21 07:00AM  
Mar-01-21 07:00AM  
Feb-22-21 07:00AM  
Jan-28-21 07:00AM  
Jan-07-21 07:00AM  
Jan-06-21 07:00AM  
Dec-10-20 08:43AM  
Dec-01-20 11:48AM  
Nov-20-20 07:00AM  
Nov-09-20 07:00AM  
Nov-05-20 05:13PM  
Oct-30-20 07:44AM  
Oct-26-20 09:22AM  
Oct-22-20 11:30AM  
Oct-05-20 07:00AM  
Sep-30-20 10:40AM  
Sep-22-20 06:45AM  
Sep-21-20 07:00AM  
Sep-18-20 09:20AM  
Sep-14-20 07:03PM  
Sep-03-20 06:20PM  
Sep-02-20 07:00AM  
Aug-28-20 10:16AM  
Aug-26-20 07:00AM  
Aug-24-20 07:00AM  
Aug-20-20 07:36AM  
Aug-18-20 08:52AM  
Aug-14-20 01:42PM  
Aug-12-20 12:20PM  
Aug-11-20 06:05PM  
Aug-10-20 05:16PM  
Aug-07-20 07:34AM  
Jul-16-20 08:56AM  
Jun-04-20 07:00PM  
Jun-03-20 09:41AM  
Jun-02-20 11:31AM  
May-22-20 11:30AM  
May-07-20 07:00AM  
May-06-20 11:30AM  
May-01-20 07:00AM  
Apr-23-20 07:00AM  
Apr-12-20 07:01AM  
Apr-07-20 09:19AM  
Mar-30-20 11:11AM  
Mar-12-20 07:01AM  
Mar-06-20 04:47PM  
Mar-05-20 05:00PM  
Feb-19-20 12:51PM  
Feb-13-20 07:00AM  
Feb-11-20 09:22AM  
Feb-10-20 09:43AM  
Feb-05-20 07:00AM  
Jan-17-20 11:56AM  
Dec-23-19 02:55PM  
Dec-12-19 07:00AM  
Nov-20-19 07:00AM  
Nov-18-19 05:05PM  
Nov-06-19 03:47PM  
Nov-04-19 07:00AM  
Oct-21-19 10:30AM  
Oct-18-19 11:04AM  
Sep-27-19 07:00AM  
Sep-20-19 08:46AM  
Sep-06-19 11:53AM  
Sep-04-19 07:41AM  
Sep-03-19 02:56PM  
Aug-29-19 11:41AM  
Aug-28-19 04:01PM  
Aug-07-19 07:00AM  
Jul-31-19 07:00AM  
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.